PEPG - The Prognosis For PepGen

2024-05-20 13:58:20 ET

Summary

• PepGen's stock has experienced extreme volatility, with an 80% drop, a 370% rebound, and subsequent decline in 14 months.
• The rebound was driven by news that Sarepta's DMD exon 51 candidate had lower skipping output than PepGen's PGN-EDO51.
• PepGen is focused on developing oligonucleotide therapies for severe neuromuscular and neurologic diseases, with two programs in human trials.
• A full investment analysis around PepGen follows in the paragraphs below.

Shares of oligonucleotide therapy concern PepGen ( PEPG ) cratered 80% from their peak, rebounded 370%, and have fallen back a bit, all in 14 months as it advances two candidates. The rebound was turbo charged by news that Sarepta’s ( SRPT ) second-generation DMD exon 51 clinical candidate only demonstrated one-sixth the skipping output of its PGN-EDO51. With data from its two programs due in 2024 against an increasingly competitive neuromuscular clinical landscape, the extreme volatility in PepGen’s stock merited further investigation. A full investment analysis and recommendation follows in the paragraphs below....

For further details see: